With the first product launched in Chinese market in 1996, Lundbeck, headquartered in Beijing, has officially settled in China since 2007. A series of medicines for brain diseases have been launched in Chinese market, including Lexapro® (depression), Ebixa® (Alzheimer’s disease), Cipramil® (depression) and Deanxit® (depression).
Lundbeck in China:
Providing high quality treatment options to help patients and caregivers.
Researching and developing new and innovative treatment options.
Investing in the development of Production & Research facilities.
Best in class continued medical education in the field of CNS diseases.